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Abstract
This study examined the efficacy of 10 % imida-
cloprid + 2.5 % moxidectin topical solution (Advan-
tage® Multi, Advocate®, Bayer) for the treatment 
of circulating microfilariae from dogs naturally 
infected with Dirofilaria immitis. The study includ-
ed two groups of 11 dogs each that consisted of two 
replicates. Replicate 1 contained 12 dogs (6 treated 
and 6 controls) and replicate 2 contained 10 dogs 
(5 treated and 5 controls). Six of the 10 dogs in 
replicate 2 were the controls from replicate 1. 
All dogs entering the study completed a physical 
examination including chest radiographs, blood 
collections for examination of Dirofilaria immitis 
circulating microfilariae, serum chemistry, com-
plete blood counts and urinalysis. To qualify for 
the study each dog was required to have a geomet-
ric mean ≥ 300 microfilariae per ml of blood from 
3 consecutive samples collected during the 8 day 
acclimation period and a heartworm disease clas-
sification of 1 or 2. Dogs were treated on study 
days 0 and 28. Post-treatment microfilarial counts 
were performed on study days 1, 2, 3, 7, 14, 21, 
28, 29, 35, and 42. Percent microfilarial reduc-
tion was determined by comparing the geometric 
mean number of circulating microfilaria remain-
ing in treated dogs with those remaining in the 
control dogs post-treatment. Seven days after the 
first treatment, the geometric mean microfilarial 
counts in treated dogs were reduced by > 99 % 
compared to the control dogs. Reduction remained 
at > 99 % through the end of the study at 42 days 
after the first treatment (14 days after the second 
treatment). The results of this study demonstrated 
that Advantage® Multi for dogs is effcacious for
treatment of circulating D. immitis microfilariae in 
naturally infected heartworm-positive dogs with no 




The removal of Dirofilaria immitis circulating 
microfilariae in conjunction with or following the 
administration of an adulticide is of paramount 
importance for improving the clinical condition of 
the dog and mitigating the spread of heartworm 
infection (McCall et al 2014). Topically applied 
Advantage® Multi for Dogs received additional 
label claims for “the treatment of Dirofilaria 
immitis circulating microfilariae in heartworm-
positive dogs and the treatment and control of 
sarcoptic mange caused by Sarcoptes scabiei var. 
canis” (Supplemental NADA 141 – 251 approved 
October 24, 2013). These claims were added to the 
original approved claims for killing adult fleas and 
the treatment and control of nematode infections, 
including fourth-stage larvae, immature adults, 
and adult stages of Ancylostoma caninum and 
Uncinaria stenocephala, fourth-stage larvae and 
adult Toxocara canis and adult Toxascaris leonina 
and Trichuris vulpis. The label also includes 
monthly use for preventing the development of 
canine heartworm disease caused by Dirofilaria 
immitis (Arther et al. 2005). The supporting data 
for this product for the treatment of dogs for 
microfilariae following transplantation of adult 
D. immitis (Pepper strain, TRS Labs, Inc, Athens, 
GA) has previously been reported (McCall et al. 
2014). In addition, a clinical field study for fur-
ther safety and efficacy evaluation was performed 
at clinical sites in Alabama, Louisiana, Missouri, 
Oklahoma, Tennessee, and Texas where the prod-
uct was used alone or in conjunction with melar-
somine dihydrochloride for removal of adult worms 
(Supplemental NADA 141 – 251 approved October 
24, 2013). The objective of the study reported here 
was to evaluate the efficacy of Advantage® Multi 
for Dogs for the treatment of circulating D. immitis 
microfilariae at the minimal labelled dose of 0.1 ml 
per kilogram body weight for naturally heartworm 
infected dogs held under laboratory conditions. 
Materials and Methods
Animals
Twenty-two (22) dogs obtained from different 
USDA licensed (U.S. Department of Agriculture 
(USDA) Animal Welfare Act (9 CFR Parts 1, 2, 
and 3) sources, that were demonstrated to have 
adequate pre-treatment mean circulating D. immi-
tis microfilariae (mff) counts of ≥ 300 mff per ml of 
blood, were included in the study and were ran-
domised to two groups of 11 animals per group. 
Animals were acclimatised at the facility at least 
8 days prior to enrollment. General health obser-
vations were conducted once daily. During the 
acclimatisation period, urinalysis was performed 
and blood was collected for serum chemistry, CBC 
(complete blood count), and for quantification of 
circulating mff using the modified Knott’s test 
(Bowman 2009). In addition, pre-treatment chest 
radiographs were performed and body weights 
were collected. These tests and examinations were 
used to determine the heartworm disease classifi-
cation for each dog. Only dogs with a heartworm 
disease Classification of 1 or 2 were included in 
the study (American Heartworm Society 2012; 
Louisiana State University School of Veterinary 
Medicine 2015). 
The dogs were housed in raised stainless steel pens 
in climate controlled rooms. The space allocation 
for each animal was in accordance with pertinent 
animal welfare guidelines or regulations set forth 
by the USDA. All pens were enclosed on top. Poly-
propylene dividers prevented animal to animal 
contact and cross contamination between pens. 
Dogs were fed a daily ration of commercial dog food 
containing 21 % protein (River Run, Cargill Animal 
Nutrition, Minneapolis, MN) and provided water 
ad libitum. Pens were cleaned daily. Temperature 
and relative humidity were recorded once daily 
using maximum-minimum thermometers and a 
portable digital thermo-hygrometer. The tempera-
tures and relative humidity were normal during 
the study. Each pen was identified with the ani-
mal ID, study number and gender. Lighting was 
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provided by overhead fluorescent lamps, and an 
automatic timer provided approximately 12 hours 
of light and 12 hours of darkness each day. General 
health observations were conducted daily beginning 
on studay day (SD) -8. The animals were main-
tained with due regard for their welfare and in 
accordance with applicable laws, regulations and 
guidelines. The protocol was approved by the Insti-
tutional Care and Use Committee prior to initiation 
of the study. The study was conducted in accordance 
with the principles of FDA Guidance for Industry 
85, Good Clinical Practice, VICH GL9, May 2001.
Study Design
This study was conducted utilising two replicates. 
Replicate 1 included 12 dogs. Replicate 2 includ-
ed 10 dogs (6 of these were dogs from the control 
group utilised from the completed Replicate 1) 
(Table 1). All dogs received a physical examina-
tion and were weighed during acclimatisation on 
SD -7 in Replicate 1 and SD -8 in Replicate 2. 
Animals were randomised on SD -1, by mean pre-
treatment mff counts to one of two study groups. 
Three pre-treatment mff counts were performed 
for each dog using the modified Knott’s test on 
Table 1:  Animal, body weight and treatment information of dogs used to determine the effects of treatment with either 
Advantage® Multi for Dogs or mineral oil on study days 0 and 28.  











13584 – 1 F 12.70 1.27 12.05 1.21
13697 – 2 M 26.75 2.68 26.95 2.70
13734 – 2 M 26.35 2.64 25.80 NA**
13777 – 2 F 31.25 3.13 30.0 3.00
13778 – 1 M 43.75 4.38 43.05 4.31
2167 – 1 F 31.00 3.10 30.75 3.08
2759 – 2 M 40.30 4.03 41.55 4.16
E7934 – 1 M 29.50 2.95 29.65 2.97
E7983 – 2 F 31.90 3.19 31.15 3.12
E7987 – 1 F 26.90 2.69 24.90 2.49
E7988 – 1 F 31.85 3.19 31.15 3.12
Mineral Oil 13680 – 1 F 24.95 2.50 24.55 2.46
13680 – 2 F 25.15 2.52 24.10 2.41
13697 – 1 M 28.20 2.82 27.00 2.70
13734 – 1 M 26.70 2.67 26.55 2.66
13792 – 2 M 28.70 2.87 26.80 2.68
2224 – 1 F 17.55 1.76 17.65 1.77
2224 – 2 F 17.35 1.74 17.75 1.78
2755 – 2 F 22.75 2.28 21.70 2.17
58101 – 1 M 20.45 2.05 23.45 2.35
58101 – 2 M 22.50 2.25 21.80 2.18
E7983 – 1 F 31.60 3.16 30.20 3.02
*ID + replicate number 
** Treatment not administered
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SDs -6, -5 and -4 (Replicate 1) and -8, -7 and -6 
(Replicate 2) (Table 2). Dogs with pre-treatment 
mean counts of at least 300 mff per mL that also 
met the other inclusion criteria were ranked 
highest to lowest by their mean pre-treatment 
mff counts. The first 2 dogs (highest counts) were 
assigned to Set 1, the next 2 dogs were assigned 
to Set 2, and so forth, until the final 2 dogs (lowest 
counts) were assigned to Set 6 for Replicate 1. 
This same allocation method was utilised for 
Replicate 2, Sets 1 through 5. 
Within the two replicates, animals in Group 1 
(treated dogs) were treated twice (once on SD 0 and 
once on SD 28) with Advantage® Multi for dogs at 
the minimum label dose (0.1 ml per kilogram body 
Table 2:  Microfilarial counts per milliliter of blood of dogs treated with Advantage® Multi for dogs or mineral oil before 
and after treatment.  The first treatment occurred on Day 0 and a second treatment occurred on Day 28.
Dog-
Replicate
Day Pre or Post Treament





1 2 3 7 14 21 28 29 35 42
Microfilariae per Milliliter of Blood
Advantage® Multi for dogs
13584 – 1 * * 4400 9000 3250 5550 12800 9850 6900 65 4 0 0 0 0 0
13697 – 2 7400 1650 6900 * * 5317 6750 9850 6500 30 4 2 12 * 3 0
13734 – 2 2650 1800 2650 * * 2367 3150 400 57 35 9 8 9 * * *
13777 – 2 16650 28800 42950 * * 29467 24300 3600 750 105 42 40 29 * 14 0
13778 – 1 * * 1000 1550 750 1100 1200 600 200 0 0 0 0 0 0 0
2167 – 1 * * 2250 1800 11650 5233 2050 3200 3200 75 0 4 14 9 6 17
2759 – 2 8650 5650 6750 * * 7017 2950 100 54 1 0 0 0 * 0 0
E7934 – 1 * * 10650 7000 12700 10117 8450 4000 3000 27 0 0 0 1 0 0
E7983 – 2 8550 2700 4650 * * 5300 15050 6950 7700 648 75 17 30 * 19 0
E7987 – 1 * * 550 1900 600 1017 200 450 350 0 0 0 0 0 0 0
E7988 – 1 * * 1350 2750 41000 15033 1050 1050 1450 9 0 0 0 0 0 0
Placebo
13680 – 1 * * 15700 9600 15900 13733 18050 28550 10600 14800 10200 22950 18250 11700 37750 10800
13680 – 2 27900 18900 5550 * * 17450 32850 36900 36450 33600 42750 34200 27450 * 28550 27450
13697 – 1 * * 9250 17400 3450 10033 7250 5250 5450 6200 5850 5600 9250 4700 4400 9450
13734 – 1 * * 1100 1900 5850 2950 1200 4500 850 4000 1000 2750 1500 3050 1150 1500
13792 – 2 31500 31050 38200 * * 33583 62100 27000 23450 16200 36450 22950 23400 * 18550 21150
2224 – 1 * * 1700 3500 25900 10367 2800 7450 5900 3450 1950 3100 1450 750 2500 11700
2224 – 2 1900 3950 3800 * * 3217 4250 3900 5600 4000 3900 5400 6000 * 6850 5800
2755 – 2 1400 7250 8700 * * 5783 9300 10300 2300 7100 3550 4950 5350 * 4900 2000
58101 – 1 * * 500 650 600 583 500 500 500 200 200 250 200 450 550 300
58101 – 2 350 450 700 * * 500 350 250 700 600 700 550 600 * 450 250
E7983 – 1 * * 900 10800 1100 4267 1250 2150 1400 350 1250 1750 7300 5400 5350 3550
* Microfilarial counts were not performed on these days from these dogs.
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weight), and Group 2 animals (control dogs) in each 
replicate were treated twice (once on SD 0 and once 
on SD 28) with mineral oil of an equivalent vol-
ume to the volume of Advantage® Multi for Dogs to 
serve as a negative control to mask the treatment 
received by the two different groups. Animals were 
reweighed on SD 27, prior to the second treatment 
(SD 28) (Table 1). 
The dogs were observed at 1, 2, 3, 4, 5, 6, 8, 12 and 
24 hours post-treatments on the days of treat-
ment on SDs 0 and 28. The dogs were observed 
once daily on all other post-treatment study days. 
Study personnel responsible for post-treatment 
safety observations and efficacy assessments were 
masked to treatment designations. Blood samples 
for mff counts were collected on SDs 1, 2, 3, 7, 14, 
21, 28, 29, 35, and 42. 
Microfilarial counts
Microfilariae were counted using the modified 
Knott’s test (Bowman 2009). Briefly after the 
Knott’s sedimentation was performed, the volume 
in the tube was adjusted to 1 ml with 2 % forma-
lin. Then 20 µl of the mixed 1 ml was examined 
for microfilariae, and, if mff were found, the count 
was multiplied by 50 to give the number per ml. 
If no mff were observed, an additional 100 µl was 
examined, and, if mff were found, the count was 
multiplied by 8.33 to determine the number of mff 
per ml. If no microfilariae were seen in the first 
120 µl volume, the entire sediment was examined 
with the total number of mff observed considered 
to be the number of mff per ml.
Data Analysis 
Percent mff reduction was determined by compar-
ing the geometric mean number of circulating mff 
remaining in Group 1 with the mff counts remain-
ing in Group 2 at post-treatment intervals on SDs 
1, 2, 3, 7, 14, 21, 28, 35, and 42.  The graph with 
mean and 95 % confidence intervals in Figure 1 was 
created by Prism version 6.04, January 17, 2014, 
GraphPad Software, Inc. 
The analysis consisted of a hierarchical assess-
ment, using the microfilarial counts made on sam-
ples collected on SDs 28 and 42. The assumption 
was, that the counts collected from samples on 
the treated animals on these two days would have 
90 % or greater reduction of the mff compared to 
the animals in the control group. For the statis-
tical comparisons, the microfilarial counts were 
transformed [log(counts+1)] and analysed with an 
analysis of covariance (ANCOVA) including terms 
for treatment (TRT) (fixed), and block and animal 
(random), using the average of the log(pre-treat-
ment count+1) values as a covariate. SAS PROC 
MIXED (SAS® version 9.2, SAS® Institute, Cary, 
NC) was used. The TRT main effect was evaluated. 
Comparisons were made between the treatment 
groups using LSMEANS, (p ≤ 0.05, two-sided). 
To provide substantial evidence of the effectiveness 
of topically applied Advantage® Multi for Dogs in 
a laboratory setting, a mff percent reduction of 
90 % or greater and a statistically significant dif-
ference between the control and treated groups 
was required at SD 42 and/or 28, and at least 6 of 
the animals in the control group were required to 
have an adequate infection of ≥ 300 mff/mL on SD 
42 and/or 28.
The efficacy evaluation was based on the per-
cent reduction of the geometric mean mf counts 
for Advantage® Multi for Dogs treated dogs when 
compared to the control dogs topically treated with 
mineral oil for each post-treatment mff count. 
Percent efficacy (or percent mff reduction) was 
determined by comparing the geometric mean mff 
counts recorded for the IVP treated groups to the 
geometric mean mff counts recorded for the control 
group using Abbott’s formula:
 % Efficacy = (N1–N2)/N1 x 100
N1: Geo. mean mff count (Control)




Microfilariae counts for the three blood samples 
collected prior to the first treatment ranged from 
500 to 33,583 mff per ml (Table 2). In the control 
dogs, at 3 days after the mineral oil application, the 
mff counts ranged from 500 to 36450 mff per ml, 
while the counts in the treated dogs ranged from 
54 to 7,700 mff per ml. A week after the first treat-
ment, the counts in the control dogs ranged from 
200 to 33,600 mff per ml while the counts in the 
Advantage® Multi for dogs treated dogs decreased 
to 0 to 648 mff per ml. By the day of the second 
treatment on SD 28, the counts in the control dogs 
ranged from 200 to 27,500 mff per ml, while in the 
treated dogs the counts ranged between 0 to 30 mff 
per ml with 5 of the 11 dogs having microfilariae. 
On SD 42, the last day of sampling, only one treated 
dog had microfilaria (17 mff per ml), while all con-
trol dogs remained positive with a range of 250 to 
27,450 mff per ml. Based on the log10 conversion of 
the mff counts a 3 log reduction in circulating mff 
was achieved by SD 14 while the mff were almost 
totally absent on SD 42 in dogs treated with Advan-
tage® Multi for dogs (Fig. 1). 
The data demonstrate that mff counts in the treat-
ed dogs were statistically reduced as compared 
to the control dogs on SDs 28 and 42, with 10 of 
the 11 control dogs with mff counts > 300 mff per 
ml on Study Day 42. In this study, mff counts in 
the treated dogs were reduced by > 99 % by SD 7, 
following one topical treatment with Advantage® 
Multi for dogs compared to the control dogs that 
received mineral oil as a treatment with the micro-
filarial reduction remaining > 99 % through SD 42 
(Table 3). The dogs treated with Advantage® Multi 
for dogs had significantly (p < 0.05) fewer micro-
filariae as compared to the control dogs on SDs 
28 and 42. 
No adverse events were observed which were con-
sidered to be treatment related. 
Discussion
Advantage® Multi for Dogs is a unique combina-
tion of the insecticide imidacloprid and the endec-
tocide moxidectin, that provides a broad spectrum 
of activity against internal and external parasites 
Fig. 1 Mean (and 95 % confi-
dence interval) of log base 10 
of microfilariae per milliliter 
of blood in two groups of 11 
dogs. One group (red circles) 
was treated twice with Advan-
tage® Multi for dogs and the 
other group was treated twice 
with a mineral oil placebo 
(green squares). The topical 
treatments were administered 
on Study Days 0 and 28; verti-
cal lines at 0 and 28 on the 
x-axis represent the days the 

























with the moxidectin component demonstrating 
high levels of efficacy against a range of stages 
and species of intestinal nematodes (Cruthers 
et al. 2008), including microfilariae of D. immitis 
(Hendrix et al. 1992). The effectiveness of 10 % 
imidacloprid / 2.5 % moxidectin in the treatment 
of dogs with micro filaria of D. repens has been 
demonstrated (Hellman et al. 2011; Traversa 
et al. 2011). Most preventive canine heartworm 
products are not given at dosages designed to be 
completely microfilaricidal (Bowman and Atkins 
2009). It has been shown that, when moxidectin 
was given at a lower dosage (3 µg/kg body weight), 
it did not demonstrate marked microfilaricidal 
activity, but with a higher dosage showed an effect 
on mff after repeated administration (Hendrix et al 
1992). Therefore, an increased dosage is necessary 
for macrocyclic lactones because microfilariae are 
typically less susceptible than immature (L3, L4) 
filariid larvae (Bowman 2012).
Table 3:  Geometric Mean Microfilariae Counts and Percent Efficacy in dogs treated with Advantage® Multi for dogs or 
mineral oil. The first treatment occurred on Day 0 and a second treatment occurred on Day 28.  
Study Day Advantage® Multi for dogs Placebo Percent Efficacy*
-8 7526.4 3826.7 NA
-7 4199.1 5968.9 NA
-6 3728.2 352.7 NA
-5 3117.9 4454.0 NA
-4 4551.5 4200.7 NA
1 3593.1 4231.7 15.1
2 1706.2 5048.8 66.2
3 980.5 3657.8 73.2
7 19.1 3451.6 99.4
14 2.4 3260.0 99.9
21 1.8 4103.8 100.0
28 2.7 4172.4 99.9**
29 0.6 2596.3 100.0
35 1.5 4376.5 100.0**
42 0.3 3906.4 100.0
NA = Not applicable;    * these numbers were rounded 
** Log MF counts significantly different between two groups (p < 0.05) using separate analysis of covariance for each study day




In this study, when dogs with circulating D. immi-
tis mff were treated with Advantage® Multi for 
Dogs on SDs 0 and 28, microfilarial counts were 
reduced by > 99 % on SD 7 following a single treat-
ment when compared to control dogs and remained 
at > 99 % through SD 42. The log of the mff counts 
were significantly lower in the Advantage® Multi 
for Dogs treated group on SDs 28 and 42 (p < 0.05) 
using separate analysis of covariance for each study 
day in comparison to counts on the control dogs. 
The results of this study demonstrated that 10 % 
imidacloprid + 2.5 % moxidectin topical solution 
(Advantage® Multi for Dogs) is efficacious for treat-
ment of circulating D. immitis mff in heartworm-
positive dogs with Class 1 or Class 2 heartworm 
disease presentation with no treatment-related 
adverse events observed.
Moxidectin is a highly lipophilic macrocyclic lac-
tone, that is stored mainly in fat tissues (Al-Azzam 
et al. 2007) and achieves high plasma concentra-
tions with gradual elimination from the host (Blag-
burn et al. 2009). Even though avermectins and 
milbemycins contain a common macrocyclic lac-
tone ring, they display different ranges of potency, 
activity and pharmacokinetics (Prichard and Rou-
let 2005). Some avermectins and moxidectin have 
unique characteristics that allow for greater flex-
ibility in use. The longer half-life and safety profile 
of moxidectin allows it to be used in long-acting 
formulations (Prichard et al. 2012), and interest 
has shifted on moxidectin as a filaricide (Geary 
and Mackenzie 2011). In a previous study, where 
dogs received adult heartworms by transplantation 
of 10 adult males and 10 adult females (Pepper 
strain, TRS Labs Inc., Athens, GA), mff counts for 
the Advantage® Multi for Dogs treated dogs were 
reduced 99.9 % following two treatments compared 
to the control group although not all treated dogs 
were totally cleared of mff on SD 42 (McCall et al. 
2014). 
Similarly, not all dogs were cleared of their mff in 
the clinical field study as detailed in the Freedom 
of Information Summary (Supplemental NADA 
141 – 251, approved October 24, 2013). The field 
study included a total of 181 dogs from the six 
states used in the evaluation of Advantage® Multi 
for Dogs as a microfilaricide. Approximately 50 % 
of the dogs received the microfilaricidal treatment 
concomitant with adulticide therapy. The treat-
ment regimen used a single injection of melar-
somine dihydrochloride two weeks (SD -14) before 
the first Advantage® Multi for Dogs application 
(SD 0), and two additional melarsomine dihydro-
chloride injections two days in a row 2 weeks after 
the first Advantage® Multi for Dogs application 
(SDs 14 and 15), and the final Advantage® Multi 
for Dogs treatment 2 weeks after the melarsomine 
dihydrochloride treatments (SD 28). In the field 
study the mff counts for efficacy evaluation were 
made on SDs -14, 28, and 42. Even though not all 
the dogs in the field study were cleared of their 
microfilariae, the overall effectiveness of two treat-
ments with Advantage® Multi for Dogs in reducing 
mff in dogs was very high, i.e., 99.3  % and 99.5 % 
on SDs 28 and 42, respectively. 
It would be prudent of the veterinary community 
to verify that the mff are eliminated after treat-
ment with Advantage® Multi for Dogs, in order 
to minimize the risk of these mff being transmit-
ted to another dog via a mosquito. It may also be 
of interest to determine if there are cases where 
recrudescence of mff occurs, if treatment of a dog 
with adult worms is terminated after one or several 
apparently successful treatments with Advantage® 
Multi for Dogs.
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